Thereafter, we wanted to elucidate how SETD2 deficiency in RCC cells could have an impact on the expression of ATG12, and potentially control to the expression of different ATG12 variants that could lead to occurrence of free ATG12 and additional ATG12-containing complexes. Here, ATG12 is linked to renal cell carcinoma.